HTG Appoints President and Chief Operating Officer

HTG Molecular Diagnostics Inc., a provider of instruments, reagents, and services for molecular profiling applications, has promoted John Lubniewski to president and chief operating officer. Lubniewski has served as HTG’s chief business officer for the past seven years, bringing over three decades of experience in the life science industry.
 
“We warmly congratulate John on his well-deserved promotion to president and chief operating officer,” said T.J. Johnson, CEO of HTG.  “John is a dynamic member of our team and widely respected in our industry. Over the last seven years, John has consistently demonstrated his capabilities and value to HTG, which will continue to serve him well in his new role as president, as he optimizes HTG’s operations for its continued growth.”
 
Lubniewski added, “I am thrilled to be working in the role of president with the team here at HTG. Our team has proven to be focused on growth and driven to succeed, and I am very motivated to build on our successes to date.”
 
Lubniewski has served as HTG’s chief business officer since April 2011. He joined HTG from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of Roche Tissue Diagnostics, or RTD. During his time at Ventana, Lubniewski served in several senior leadership roles and was responsible for marketing and global accountability for all clinical assay products. Prior to the acquisition by Roche, Lubniewski was responsible for a variety of assay and platform development and commercialization efforts across the company. Prior to Ventana, Lubniewski spent over a decade working at Corning Inc., a manufacturing company, in a variety of roles including divisional, sector, and corporate sales, and marketing. Lubniewski earned a bachelor of science degree in chemical engineering from Clarkson University.
 

HTG is focused on next-generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.